BridgeBio Pharma, Inc. Interest Expense
BridgeBio Pharma, Inc. (BBIO) reported Interest Expense of $22.94 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-01.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-08-01
- BridgeBio Pharma, Inc. interest expense for the quarter ending 2024-06-30 was $22.94M, a 11.38% increase year-over-year.
- BridgeBio Pharma, Inc. interest expense for the quarter ending 2024-03-31 was $23.47M, a 16.65% increase year-over-year.
- BridgeBio Pharma, Inc. interest expense for the quarter ending 2023-12-31 was $20.27M, a 1.39% increase year-over-year.
- BridgeBio Pharma, Inc. interest expense for the quarter ending 2023-09-30 was $20.31M, a 2.43% increase year-over-year.
- BridgeBio Pharma, Inc. interest expense for fiscal 2023 was $81.29M, a 1.06% increase from fiscal 2022.
- BridgeBio Pharma, Inc. interest expense for fiscal 2022 was $80.44M, a 71.96% increase from fiscal 2021.
- BridgeBio Pharma, Inc. interest expense for fiscal 2021 was $46.78M, a 27.62% increase from fiscal 2020.
- BridgeBio Pharma, Inc. interest expense for fiscal 2020 was $36.66M, a 318.20% increase from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $22.94M 10-Q · filed 2024-08-01 | $46.41M 10-Q · filed 2024-08-01 | $66.68M derived: sum of 3 quarters · filed 2024-08-01 | $86.98M derived: sum of 4 quarters · filed 2024-08-01 |
| 2024-03-31 | $23.47M 10-Q · filed 2024-05-02 | $43.74M derived: sum of 2 quarters · filed 2024-05-02 | $64.05M derived: sum of 3 quarters · filed 2024-05-02 | $84.64M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-12-31 | $20.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $40.57M derived: sum of 2 quarters · filed 2024-02-22 | $61.17M derived: sum of 3 quarters · filed 2024-08-01 | $81.29M 10-K · filed 2024-02-22 |
| 2023-09-30 | $20.31M 10-Q · filed 2023-11-02 | $40.90M derived: sum of 2 quarters · filed 2024-08-01 | $61.02M 10-Q · filed 2023-11-02 | $81.01M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-06-30 | $20.59M 10-Q · filed 2024-08-01 | $40.72M 10-Q · filed 2024-08-01 | $60.70M derived: sum of 3 quarters · filed 2024-08-01 | $80.53M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $20.12M 10-Q · filed 2024-05-02 | $40.11M derived: sum of 2 quarters · filed 2024-05-02 | $59.94M derived: sum of 3 quarters · filed 2024-05-02 | $80.22M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $19.99M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $39.81M derived: sum of 2 quarters · filed 2024-02-22 | $60.09M derived: sum of 3 quarters · filed 2024-02-22 | $80.44M 10-K · filed 2024-02-22 |
| 2022-09-30 | $19.82M 10-Q · filed 2023-11-02 | $40.10M derived: sum of 2 quarters · filed 2023-11-02 | $60.45M 10-Q · filed 2023-11-02 | $75.58M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $20.28M 10-Q · filed 2023-08-03 | $40.62M 10-Q · filed 2023-08-03 | $55.76M derived: sum of 3 quarters · filed 2024-02-22 | $66.82M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $20.34M 10-Q · filed 2023-05-04 | $35.48M derived: sum of 2 quarters · filed 2024-02-22 | $46.55M derived: sum of 3 quarters · filed 2024-02-22 | $57.38M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $15.13M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $26.20M derived: sum of 2 quarters · filed 2024-02-22 | $37.04M derived: sum of 3 quarters · filed 2024-02-22 | $46.78M 10-K · filed 2024-02-22 |
| 2021-09-30 | $11.07M 10-Q · filed 2022-11-03 | $21.91M derived: sum of 2 quarters · filed 2022-11-03 | $31.64M 10-Q · filed 2022-11-03 | $42.61M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $10.84M 10-Q · filed 2022-08-04 | $20.58M 10-Q · filed 2022-08-04 | $31.54M derived: sum of 3 quarters · filed 2023-02-23 | $42.47M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $9.74M 10-Q · filed 2022-05-05 | $20.70M derived: sum of 2 quarters · filed 2023-02-23 | $31.63M derived: sum of 3 quarters · filed 2023-02-23 | $42.38M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $10.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $21.89M derived: sum of 2 quarters · filed 2023-02-23 | $32.65M derived: sum of 3 quarters · filed 2023-02-23 | $36.66M 10-K · filed 2023-02-23 |
| 2020-09-30 | $10.93M 10-Q · filed 2021-11-04 | $21.68M derived: sum of 2 quarters · filed 2021-11-04 | $25.69M 10-Q · filed 2021-11-04 | $28.73M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $10.75M 10-Q · filed 2021-08-05 | $14.76M 10-Q · filed 2021-08-05 | $17.80M derived: sum of 3 quarters · filed 2022-02-25 | $19.92M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $4.01M 10-Q · filed 2021-05-06 | $7.05M derived: sum of 2 quarters · filed 2022-02-25 | $9.16M derived: sum of 3 quarters · filed 2022-02-25 | $11.10M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $5.15M derived: sum of 2 quarters · filed 2022-02-25 | $7.09M derived: sum of 3 quarters · filed 2022-02-25 | $8.77M 10-K · filed 2022-02-25 |
| 2019-09-30 | $2.11M 10-Q · filed 2020-11-05 | $4.05M derived: sum of 2 quarters · filed 2020-11-05 | $5.72M 10-Q · filed 2020-11-05 | $6.90M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $1.94M 10-Q · filed 2020-08-11 | $3.61M 10-Q · filed 2020-08-11 | $4.79M derived: sum of 3 quarters · filed 2021-02-25 | $5.95M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $1.67M 10-Q · filed 2020-05-14 | $2.85M derived: sum of 2 quarters · filed 2021-02-25 | $4.01M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2018-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.33M derived: sum of 2 quarters · filed 2021-02-25 | $2.55M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $1.16M 10-Q · filed 2019-11-08 | $1.37M 10-Q · filed 2019-11-08 | ||
| 2017-12-31 | $13.00K 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |